scholarly journals An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis

2020 ◽  
Vol 22 (6) ◽  
pp. 504-514
Author(s):  
Marina V. Shestakova ◽  
Alexey S. Kolbin ◽  
Oleg I. Karpov ◽  
Gagik R. Galstyan ◽  
Alexander Y. Mayorov ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Diabetes Mellitus Type 2 ◽  
Glycated Hemoglobin ◽  
Fasting Blood Glucose ◽  
False Negative ◽  
Diabetes Mellitus Type ◽  
Test Execution ◽  
Hba1c Test ◽  
Negative Results

BACKGROUND: Diagnostic of diabetes mellitus type 2 (DM2T) in time is very actual for treatment and prevention of potential complications of illness. Fasting blood glucose test (FBG) is a widely used method of primary DM2T diagnose. Glycated hemoglobin (HbA1c) test is an alternative and used more rarely due to expensive. AIM: Modelling of comparative expenditures for DM2T control in cases of primary diagnostic by HbA1c test or FBG test usage in 20-years horizon. METHODS: Retrospective analysis of aggregated epidemiological Russian NATION study data in 810 patients with prediabetes and DM2T with both analysis performed, with sensitivity and specificity of each is detected. The simulation model of DM2T outcomes has been used for Health Technology assessment (direct and indirect costs of Diabetes control during 20 years). Three algorithms of the DM2T treatment were investigated for understanding of expenditures in case on diagnostic on-time and case of late verification with metformin, gliflozines, gliptins, Glucagon-like peptide-1 receptor agonists, basal insulin analogs and their combinations. RESULTS: FBG test has more negative results for DM2T diagnostics in compare with HbA1c analysis (77,4% and 36,5% accordingly). Amount of false negative results in FBG test in 3 times more often occurred in comparison with HbA1c. HbA1c test in 3 times more precisely than FBG test for carbon metabolism abnormalities detection. Diagnostic in time with HbA1c test in compare with late process of illness detection by FBG can cut common expenditures on 26,3-27,7% depending on treatment option due to macrovasular complications decreasing. Disability rate is expected decrease on 21% to 20-th year in case of diagnostic with HbA1c performing instead FBG test. CONCLUSION: HbA1c test has diagnostic advantages in compare with FBG test for primary investigation (dispanserization). Direct and indirect expenditures in average for one patient with DM2T on 20-years horizon including cost of drugs, analysis, complications, disabilities are less in case of diagnostic in time with HbA1c test in comparison with late diagnostics in case of FBG test execution.

scholarly journals The importance of HbA1C test in prediabetes with special reference to Purvarupavastha of Prameha-A literary review

AYUSHDHARA ◽  
2021 ◽  
pp. 3574-3580
Author(s):  
Archana R.Gharge ◽  
Rajiv Mundane
Keyword(s):  
Diabetes Mellitus ◽  
Diabetes Mellitus Type 2 ◽  
Early Stage ◽  
Diabetes Mellitus Type ◽  
Glucose Levels ◽  
Blood Tests ◽  
Hba1c Test ◽  
Blood Glucose Levels ◽  
Premonitory Symptoms

Diabetes mellitus is a metabolic disorder causing hyperglycaemia with defect in metabolism of carbohydrates, fats, and proteins due to defect in insulin secretion, or its utilization or both. Prediabetes is a condition in which the blood glucose levels do not meet the criteria for diabetes or too high to be considered normal (ADA). It is an early stage of DM. So it is important to diagnose Diabetes Mellitus type 2 in the previous stage that is prediabetes. It is already in practice to diagnose it with laboratory blood tests. But additionally, we can also take help of Prameha purvarupas as premonitory symptoms in patients prediabetes. HbA1C is a useful parameter to diagnose prediabetes. There is mild or no symptoms mentioned for prediabetes. Purvarupas of Prameha mentioned in Ayurvedic samhitas can be useful to know early stage of Diabetes mellitus type 2, clinically. The purpose of this article is to highlight the importance of Purvarupa of Prameha to diagnose prediabetes. So, the need of hour is to focus on screening and diagnosing pre-Diabetes earlier, by spreading knowledge and awareness among society which will play a key role to reduce the conversion of pre-diabetes to diabetes mellitus.

Studi Preeliminari Suplementasi Produk Herbal Antidiabetes Terhadap Kontrol Glikemik Pasien Diabetes Mellitus Tipe II

2021 ◽  
Vol 16 (1) ◽  
pp. 91
Author(s):  
Yayuk Andayani ◽  
Siti Rahmatul Aini ◽  
Iman Surya Pratama ◽  
Ni Made Ratnata Amalia ◽  
Lalu Husnul Hidayat
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Diabetes Mellitus Type 2 ◽  
Fasting Blood Glucose ◽  
Herbal Product ◽  
Randomised Clinical Trial ◽  
Diabetes Mellitus Type ◽  
Control Group ◽  
Diabetes Mellitus Type Ii

The aim of this preliminary study is to compare the effect of supplement herbal product (contained the combination of extract Phaesolus vulgaris  and Momordica charantia) and control for short term glycemic control in patient with diabetes mellitus type 2. A randomised clinical trial using paralel design subject has been done in patient with diabetes mellitus type II that meet inclusion criteria (n=60, each group consist of 30 patients). The research held on two public health center in Mataram. The participant alocated on two groups which are the group that got oral hypoglicemic medicine with the herbal product and the control group that only got oral hypoglicemic medicine. The character demographic of the patient and the result of the therapy was obtained by patient interviewed and physical assesment. Fasting Blood Glucose was measured on day 0, 7 and 14. The character demographic was analyzed using chi squared test, and there were no signifficant different on both treated and controlled group (p>0,05). There were also no signifficant different found between control and the treated group (0.73 ± 93,06 ;23,83 ± 100,94) on day 7 and day 14 analyzed using t-test. According to this study, the combination between supplement herbal product and oral hypoglicemic medicine does not improved glycemic control on patient with diabetes mellitus type 2. Bias in this studies encourages improvement in design and management of further studies. 

Bone quality in diabetes mellitus type 2

2014 ◽  
Author(s):  
Peter Jackuliak ◽  
Zdenko Killinger ◽  
Juraj Payer
Keyword(s):  
Diabetes Mellitus ◽  
Bone Quality ◽  
Diabetes Mellitus Type 2 ◽  
Diabetes Mellitus Type
Sign in / Sign up

Export Citation Format

Share Document